| Molecular mimicry and autoimmunity |
46 |
| Systemic lupus erythematosus: Diagnosis and clinical management |
43 |
| A cellular and molecular view of T helper 17 cell plasticity in autoimmunity |
35 |
| Th17 plasticity and its relevance to inflammatory bowel disease |
34 |
| A comprehensive review on adult onset Still's disease |
32 |
| Connecting the immune system, systemic chronic inflammation and the gut microbiome: The role of sex |
28 |
| A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity |
27 |
| Innately versatile: gamma delta 17 T cells in inflammatory and autoimmune diseases |
25 |
| Molecular mechanisms underpinning T helper 17 cell heterogeneity and functions in rheumatoid arthritis |
24 |
| Shared gut, but distinct oral microbiota composition in primary Sjogren's syndrome and systemic lupus erythematosus |
22 |
| Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients |
22 |
| The treatment of anti-phospholipid syndrome: A comprehensive clinical approach |
20 |
| Etiopathogenesis of autoimmune hepatitis |
20 |
| The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review |
20 |
| Clinical significance and immunobiology of IL-21 in autoimmunity |
19 |
| Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases |
19 |
| Th17 cells in primary Sjogren's syndrome: Pathogenicity and plasticity |
18 |
| Bystander activation and autoimmunity |
17 |
| Serum microRNA screening and functional studies reveal miR-483-5p as a potential driver of fibrosis in systemic sclerosis |
17 |
| The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus |
16 |
| Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study |
16 |
| A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease |
15 |
| The immunobiology of autoimmune encephalitides |
15 |
| Inflammasomes and autoimmune and rheumatic diseases: A comprehensive review |
14 |
| Neutrophil extracellular traps exert both pro- and anti-inflammatory actions in rheumatoid arthritis that are modulated by Clq and LL-37 |
14 |
| IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid |
14 |
| Tolerogenic Ag-PLG nanoparticles induce tregs to suppress activated diabetogenic CD4 and CD8 T cells |
14 |
| Immunological effects of vitamin D and their relations to autoimmunity |
14 |
| Activin-A in the regulation of immunity in health and disease |
14 |
| Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes |
13 |
| Autophagy: A new concept in autoimmunity regulation and a novel therapeutic option |
13 |
| Interferon alpha: The key trigger of type 1 diabetes |
13 |
| Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells |
13 |
| Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients |
12 |
| Overall survival and mortality risk factors in Takayasu's arteritis: A multicenter study of 318 patients |
12 |
| Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - A report of two cases |
12 |
| Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells |
12 |
| Abatacept modulates CD80 and CD86 expression and memory formation in human B-cells |
12 |
| Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis |
11 |
| The immunobiology of mucosal-associated invariant T cell (MAIT) function in primary biliary cholangitis: Regulation by cholic acid induced Interleukin-7 |
11 |
| Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature |
11 |
| Small non-coding RNAs as important players, biomarkers and therapeutic targets in multiple sclerosis: A comprehensive overview |
11 |
| Autoimmune epithelitis (Sjogren's syndrome); the impact of metabolic status of glandular epithelial cells on auto-immunogenicity |
11 |
| Th17 cells, gamma delta T cells and their interplay in EAE and multiple sclerosis |
11 |
| Il-23/Th17 cell pathway: A promising target to alleviate thymic inflammation maintenance in myasthenia gravis |
10 |
| Systemic activation of NLRP3 inflammasome in patients with severe primary Sjogren's syndrome fueled by inflammagenic DNA accumulations |
10 |
| Characterization of Blimp-1 function in effector regulatory T cells |
10 |
| T cells are influenced by a long non-coding RNA in the autoimmune associated PTPN2 locus |
10 |
| Autotaxin and chronic inflammatory diseases |
10 |
| Efficacy of the anti-IL 17 secukinumab in refractory Behcet's syndrome: A preliminary study |
10 |
